You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Diabetes Articles
Popular Diabetes Articles
Highly Recommended Diabetes Articles
Send a link to this page to your friends and colleagues.
Boehringer Ingelheim and Eli Lilly have begun sales of Tradjenta, a drug for type 2 diabetes, in U.S. pharmacies. The drug (generic name linagliptin) comes in tablet form and is intended to compete with Amylin Pharmaceuticals' Byetta, which is injected, and Merck's Januvia, which also competes with Byetta. Both are well-established in the U.S. market.
Like Januvia, Tradjenta is a DPP-4 inhibitor that blocks an enzyme that interferes with a hormone that stimulates after-meal insulin production. This leads to more insulin in the bloodstream, which lowers blood glucose levels.
The new drug was tested in eight double-blind, placebo-controlled studies that involved 3,800 type 2 patients. It was tested as a standalone therapy and in combination with such standard diabetes drugs as metformin and glimepiride. It is likely that in most cases, Tradjenta will be prescribed as an adjunct to, rather than a replacement for, other drugs.
Despite competing head-to-head against well-established drugs, Tradjenta does bring one competitive advantage to the table: It is taken only once daily and does not pass through the kidneys on the way to excretion. Instead, the drug is expressed through bile and the gut, which makes it safe for patients with kidney problems.
2 comments - Jul 27, 2011
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.